Targeting MD2 in prostate cancer bone metastasis: Mechanistic insights and therapeutic potential (IMAGE)
Caption
Figure 3: Immunohistochemistry (IHC) and Immunofluorescence (IF) analysis of MD2 expression and immune cell infiltration in prostate cancer tissues.
(Upper panel) Representative IF images showing myeloid-derived suppressor cells (MDSCs; CD11b/CD33) and corresponding IHC staining for MD2 in patient tissues with varying prostate cancer (PCa) grades, metastatic lesions, and histologically normal adjacent tissue (NAT). (Lower panel) Representative IF images showing regulatory Tcell (Treg; CD25/Foxp3) infiltration and corresponding IHC staining for MD2 in PCa tissues with different tumor grades, metastasis, and NAT.
Credit
Copyright: © 2026 Dattilo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Usage Restrictions
With credit to the original source.
License
Original content